池田 樹生

A Prospective Comparison of Azilsartan and Amlodipine for Bevacizumab-induced Hypertension and Proteinuria in Colorectal Cancer. 

In vivo (Athens, Greece) 40(1) 465-473 2026年  査読有り

Timing of bone-modifying agents after bone metastasis diagnosis and time to first skeletal-related event: A systematic review and study-level correlation analysis. 

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 10781552251399902-10781552251399902 2025年12月23日  査読有り

Potential role of endothelial dysfunction in hypertension and proteinuria in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab: a pilot prospective observational study. 

Cancer chemotherapy and pharmacology 95(1) 55-55 2025年4月17日  査読有り

Clinical characteristics of patients requiring emergency hospitalization due to immune-related adverse events: a retrospective study 

Journal of Pharmaceutical Health Care and Sciences 10(1) 2024年12月18日  査読有り筆頭著者

[Patient Questionnaire Survey of"As-Needed"Medications to Relieve Side Effects and Anxiety for Breast Cancer Chemotherapy]. 

Gan to kagaku ryoho. Cancer & chemotherapy 51(8) 815-819 2024年8月  査読有り筆頭著者

Plasma endothelin-1 may predict bevacizumab-induced proteinuria in patients with colorectal cancer. 

Cancer chemotherapy and pharmacology 91(5) 427-434 2023年5月  査読有り